NPS Pharmaceuticals, Inc. NPSP, a biopharmaceutical company
pioneering and delivering therapies that transform the lives of patients with
rare diseases worldwide, today announced that it has established a
patient-centric distribution and clinical service network for Gattex^®
(Teduglutide [rDNA origin]) for Injection, for subcutaneous use. The network
is comprised of leading specialty home infusion providers, including Accredo
Health Group, Inc.; BioScrip; Inc.; Coram, LLC; ThriveRx; and Walgreens
Infusion Services. In addition to dispensing Gattex, the company's contracted
providers will provide clinical services to support the use of Gattex in
reducing dependence on parenteral nutrition (PN) and intravenous fluids (IV)
for patients with short bowel syndrome (SBS). Gattex was approved by the U.S.
Food and Drug Administration (FDA) on December 21, 2012 as a treatment for
adults with SBS who are dependent on parenteral support. Gattex is the
first-and-only FDA-approved therapy for the long-term treatment of SBS and the
first major treatment advance for SBS in nearly 40 years.
By adding Gattex to their product offering the company's contracted home
infusion providers will offer a wide range of personalized services to
PN-dependent patients with short bowel syndrome through an interdisciplinary
team of experienced infusion professionals, including nurses, pharmacists,
dietitians, and support professionals.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in